EcoDrugPlus

Calcium Voltage-Gated Channel Auxiliary Subunit Beta 1

Ensembl ID : ENSDNOG00000043733
Gene Symbol: CACNB1
2 Cross references
210 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Beta 3

Ensembl ID : ENSDNOG00000043665
Gene Symbol: CACNB3
4 Cross references
278 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Beta 4

Ensembl ID : ENSDNOG00000015978
Gene Symbol: CACNB4
2 Cross references
251 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 1

Ensembl ID : ENSDNOG00000048442
Gene Symbol: CACNG1
4 Cross references
268 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 2

Ensembl ID : ENSDNOG00000034297
Gene Symbol: CACNG2
4 Cross references
262 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 3

Ensembl ID : ENSDNOG00000041804
Gene Symbol: CACNG3
2 Cross references
258 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 4

Ensembl ID : ENSDNOG00000031387
Gene Symbol: CACNG4
4 Cross references
259 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 5

Ensembl ID : ENSDNOG00000036324
Gene Symbol: CACNG5
2 Cross references
251 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 7

Ensembl ID : ENSDNOG00000047587
Gene Symbol: CACNG7
2 Cross references
257 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 8

Ensembl ID : ENSDNOG00000011867
Gene Symbol: CACNG8
2 Cross references
243 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 A

Ensembl ID : ENSDNOG00000041857
Gene Symbol: CACNA1A
2 Cross references
270 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 C

Ensembl ID : ENSDNOG00000008728
Gene Symbol: CACNA1C
2 Cross references
212 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).